02156nas a2200217 4500000000100000008004100001260003400042653005700076653002700133653002100160653002100181653006100202653002300263100001400286245008700300856009200387300001200479490000700491520141500498022002501913 2020 d bOxford University Press (OUP) 10 aPublic Health, Environmental and Occupational Health 10 aHealth(social science) 10 aGeneral Medicine 10 aHealth economics 10 aGlobal program to eliminate lymphatic filariasis (GPELF) 10 acost-effectiveness 1 aTurner HC 00 aHealth economic analyses of the Global Programme to Eliminate Lymphatic Filariasis uhttps://academic.oup.com/inthealth/article-pdf/13/Supplement_1/S71/35056144/ihaa095.pdf aS71-S74 0 v13 3 aAbstract
The Global Programme to Eliminate Lymphatic Filariasis (GPELF) was established by the WHO in 2000. It aims to eliminate lymphatic filariasis as a public health problem. This paper summarises the key estimates of the cost-effectiveness and economic benefits related to the mass drug administration (MDA) provided by the GPELF. Several studies have investigated the cost-effectiveness of this MDA, estimating the cost per disability-adjusted life year (DALY) averted. These cost-effectiveness estimates have consistently classed the intervention as cost-effective and as favourable compared with other public health interventions conducted in low- and middle-income countries. Studies have also found that the MDA used for lymphatic filariasis control generates significant economic benefits. Although these studies are positive, there are still important gaps that warrant further health economic research (particularly, the evaluation of alternative interventions, further evaluation of morbidity management strategies and evaluation of interventions for settings coendemic with Loa loa). To conclude, health economic studies for a programme as large as the GPELF are subject to uncertainty. That said, the GPELF has consistently been estimated to be cost-effective and to generate notable economic benefits by a number of independent studies. a1876-3413, 1876-3405